October 3, 2022
Astellas Pharma said on September 30 that the European Medicines Agency (EMA) has accepted for review the drug maker’s application for its fezolinetant for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause. If approved, the drug...read more